First Round News Hubb
Advertisement Banner
  • Home
  • First Round News
  • Funding News
  • Contact
No Result
View All Result
  • Home
  • First Round News
  • Funding News
  • Contact
No Result
View All Result
First Round News Hubb
No Result
View All Result
Home Funding News

Female founded Temedica collects €25M to help companies offer personalised medicine

admin by admin
November 25, 2022
in Funding News



Temedica, a Munich-based health insights company, has raised €25M in a Series B funding round led by MIG Capital and a Munich-based family office. The latest round brings the total fund raised to date to €42M.

The company will use the funds to accelerate the expansion of its ecosystem, which provides holistic insights into the care realities and patient journeys of millions of patients by combining health-related data, and its development efforts.

Gloria Seibert, founder & CEO of Temedica, says, “Temedica’s vision is to make a pioneering contribution to the development of personalised medicine by linking health-relevant data to new, evidence-based insights. We are convinced that big data sets and completely new data types, such as patient-generated data from large populations outside of classic clinical trials, play a key role. These enable new knowledge and understanding of diseases and their actual courses. I am very pleased that our investors share this vision and accompany and support us as we continue to expand the Temedica ecosystem.”

Health insight platform

Established by Gloria Seibert and Benjamin Friedrich in 2016, Temedica is a health insights company whose mission is to enable personalised and individualised medicine, focusing on patients and their needs.

The company achieves this by linking health-related data from various sources, which are processed into valuable insights in compliance with the GDPR.

From more than 40 billion data points on over 50,000 diagnoses, the German company derives health-related insights on issues such as disease progression, treatment effectiveness, patient journeys, and medication adherence.

The Temedica ecosystem brings together data from various sources, such as registry data, sales data of medically relevant products, insurance data, patient experience data, and – with explicit patient consent – patient-generated data from patient companion apps.

As per the company’s claims, the information and insights collected by them are channeled back to patients via Temedica’s patient companion apps.

Boris Bernstein, Partner at MIG Capital, says, “Temedica is operating in a massively growing and highly attractive market. The newly developed real-world insights platform Permea provides pharmaceutical companies with a deep understanding of patients and their care in the real world, outside of clinical trials. Access to this unique 360° understanding of care realities has the potential to revolutionize our healthcare system as we know it. The team at Temedica is highly motivated and goal-oriented, and we are excited to work with them and continue our journey together.”

The post Female founded Temedica collects €25M to help companies offer personalised medicine appeared first on Tech Funding News.



Source link

Previous Post

Generative AI and the exponential growth of content

Next Post

Accelerating Digital Transformation: Simple Solutions for Problems

Next Post

Accelerating Digital Transformation: Simple Solutions for Problems

Recommended

Asia, Africa and LatAm set to get $425-mn energy-focused fund-of-funds

1 month ago

Zipari Names Tabatha Erck as Next Chief Executive

4 months ago

Altris AI helps prevent blindness with its AI diagnostics solution, lands $1M

2 months ago

AiAdvertising Campaign Performance Platform Helps Drive Results

3 months ago

The Capital Quest | Cypher Capital backs UAE’s Rekt; Ibtikar Fund bets on Jordanian startup

3 months ago

The Capital Quest | Abu Dhabi’s IHC brings Infinity Wave on board as key shareholder

2 months ago

first-round-white

© 2022 First Round News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • First Round News
  • Funding News
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • First Round News
  • Funding News
  • Contact

© 2022 First Round News Hubb All rights reserved.